Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PKI
|
|||
| Former ID |
DIB012872
|
|||
| Drug Name |
EV-077
|
|||
| Synonyms |
EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
Evolva SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Thromboxane-A synthase (TBXAS1) | Target Info | Modulator | [2] |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Platelet activation | ||||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Arachidonic acid metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| Eicosanoid Synthesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01551381) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Company report (Pharmaceuticalintelligence) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.